Enzon Pharmaceuticals, Inc. (ENZN)

OTCMKTS: ENZN · Delayed Price · USD
0.134
-0.002 (-1.71%)
Jun 2, 2023, 1:55 PM EDT - Market closed
Market Cap 20.12M
Revenue (ttm) 26,000
Net Income (ttm) 392,000
Shares Out 74.21M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,850
Open 0.143
Previous Close 0.136
Day's Range 0.134 - 0.149
52-Week Range 0.120 - 0.450
Beta 0.19
Analysts n/a
Price Target n/a
Earnings Date Mar 18, 2013

About ENZN

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 15, 1984
Country United States
Stock Exchange OTCMKTS
Ticker Symbol ENZN
Full Company Profile

Financial Performance

In 2022, ENZN's revenue was $26,000, a decrease of -96.29% compared to the previous year's $701,000. Losses were -$186,000, -60.34% less than in 2021.

Financial Statements

News

Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon's CFO, to Assume Position of CEO and Remain CFO

CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Com...

2 years ago - GlobeNewsWire

Enzon Pharmaceuticals Announces Results of Rights Offering

Looking to Next Step – Acquisition Opportunities Looking to Next Step – Acquisition Opportunities

2 years ago - GlobeNewsWire

Enzon Pharmaceuticals Announces Key Dates for Rights Offering

CRANFORD, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced today the record date and expected subscription period for its previous...

2 years ago - GlobeNewsWire
}

Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting

CRANFORD, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its 2020 annual meeting of stockholders (the “Annual Meeting...

2 years ago - GlobeNewsWire

Enzon Pharmaceuticals Anticipated Rights Offering to Existing Shareholders

CRANFORD, N.J., Aug. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC: ENZN) today announced that its Board of Directors (the “Board”) has approved a rights o...

3 years ago - GlobeNewsWire

Enzon Pharmaceuticals, Inc. Adopts Tax Benefits Preservation Plan to Protect its NOL Assets and Shareholder Value

CRANFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its Board of Directors (the “Board”) adopted a tax benefits p...

3 years ago - GlobeNewsWire